Low dose combination treatment of Cpd-4 (30 mg/kg) and cisplatin (2 mg/kg) presented significantly better anti-tumor efficacy than either monotherapy with TGI of 86.2%, indicating a synergistic effect with acceptable tolerability (Figures 4C, D). The gene discussed is INPP5E; the disease is neoplasm.